title: Stratifying osteosarcoma: minimizing and maximizing therapy.
abstract: Patients who are newly diagnosed with osteosarcoma face a daunting year of medical and surgical therapy, often filled with hospitalizations and changes in lifestyle. Fortunately, the majority of patients endure this struggle to become long-term survivors. However, follow-up studies of cancer survivors are revealing the sequelae of this curative therapy. Just as disturbingly, there remains a large subset of patients for whom conventional therapy is inadequate and who succumb to disease. In this review, we propose that therapeutic strategies for osteosarcoma patients must rely on stratification of patients into risk categories, in order to minimize therapy for some, while expanding treatment for others. We then focus on two molecular targets for the treatment of patients with high-risk osteosarcoma.
authors.affiliation: Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive,Bethesda, MD 20892, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Niswander
authors.forename: Su Young
authors.initials: SY
authors.lastname: Kim
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors; D012516:Osteosarcoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D017741:Survivors; D000077204:Temozolomide; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D007211:Indoles
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003606:Dacarbazine; D016023:Integrins; D011799:Quinazolines; D040262:Receptors, Vascular Endothelial Growth Factor; D000077204:Temozolomide; D042461:Vascular Endothelial Growth Factor A; C500926:cediranib; D007211:Indoles
references.citation: Int J Oncol. 2008 Aug;33(2):253-9
references.pmid: 18636145
references.citation: Nat Rev Clin Oncol. 2009 Sep;6(9):507-18
references.pmid: 19636328
references.citation: J Bone Joint Surg Am. 1967 Jan;49(1):101-10
references.pmid: 5225072
references.citation: Expert Rev Anticancer Ther. 2009 Apr;9(4):511-23
references.pmid: 19374604
references.citation: J Clin Oncol. 2002 Feb 1;20(3):776-90
references.pmid: 11821461
references.citation: J Clin Oncol. 2008 Jan 20;26(3):399-405
references.pmid: 18202416
references.citation: Nat Rev Cancer. 2008 Feb;8(2):147-56
references.pmid: 18202698
references.citation: Mod Pathol. 2006 May;19(5):738-45
references.pmid: 16528367
references.citation: Nat Rev Cancer. 2010 Jan;10(1):9-22
references.pmid: 20029421
references.citation: Anticancer Res. 2007 Jan-Feb;27(1A):155-64
references.pmid: 17352227
references.citation: Eur J Cancer. 2010 Mar;46(5):901-11
references.pmid: 20061136
references.citation: J Clin Oncol. 1997 Jan;15(1):76-84
references.pmid: 8996127
references.citation: Ann Oncol. 2008 Apr;19(4):807-13
references.pmid: 18056650
references.citation: Anticancer Drugs. 2009 Nov;20(10):851-5
references.pmid: 19826350
references.citation: Cell. 1996 Aug 9;86(3):353-64
references.pmid: 8756718
references.citation: Curr Opin Oncol. 2007 Jul;19(4):341-6
references.pmid: 17545797
references.citation: Pediatr Blood Cancer. 2008 Mar;50(3):581-7
references.pmid: 17457854
references.citation: Cancer Metastasis Rev. 2005 Sep;24(3):413-23
references.pmid: 16258729
references.citation: Cancer Res. 2007 Feb 15;67(4):1645-52
references.pmid: 17308105
references.citation: Expert Rev Mol Med. 2010 Jan 18;12:e3
references.pmid: 20078909
references.citation: Future Oncol. 2009 May;5(4):421-32
references.pmid: 19450171
references.citation: J Clin Oncol. 1994 Dec;12(12):2614-20
references.pmid: 7989936
references.citation: Cell. 2006 Aug 11;126(3):489-502
references.pmid: 16901783
references.citation: BMC Genomics. 2009 Dec 23;10:625
references.pmid: 20028558
references.citation: Cell. 2002 Sep 20;110(6):673-87
references.pmid: 12297042
references.citation: Curr Oncol Rep. 2008 Jul;10(4):350-8
references.pmid: 18778562
references.citation: Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
references.pmid: 15459662
references.citation: Clin Cancer Res. 2000 Feb;6(2):572-7
references.pmid: 10690541
references.citation: Hum Pathol. 2006 Aug;37(8):1009-14
references.pmid: 16867863
references.citation: J Bone Joint Surg Am. 1970 Apr;52(3):411-23
references.pmid: 5269156
references.citation: Int J Cancer. 2005 Dec 20;117(6):883-8
references.pmid: 16152621
references.citation: PLoS Med. 2009 Oct;6(10):e1000161
references.pmid: 19823573
references.citation: Cancer Res. 2005 May 15;65(10):4389-400
references.pmid: 15899831
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: Oncogene. 2009 Sep 24;28(38):3401-11
references.pmid: 19597468